A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Clinical trial NCT05684211 · UNKNOWN
Trial details
- NCT number
- NCT05684211
- Sponsor
- Shanghai Celfuture Biotech Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-01
- Primary completion
- 2023-01-01
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.